

NEW DRUGS

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

中国新药杂志
二〇二〇年
第二十九卷
第十五期
第1681-1800页
半月刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6

中国新药杂志



15
2020
Vol.29 | No.15

- 欧洲前沿疗法药物的监管、审批及其启示
- FDA对我国药品生产企业检查分析
- 关于流感疫苗保护性临床试验必要性的考虑
- 新型冠状病毒肺炎相关临床试验研究进展
- 帕博利珠单抗注射液治疗恶性黑色素瘤安全性的Meta分析

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



万方数据

目次

半月刊 1992年创刊
第29卷第15期 2020年8月15日出版

•新药述评与论坛•

- 1681 欧洲前沿疗法药物的监管、审批及其启示·····陈云, 李珊珊, 邵蓉, 等
1691 高值创新药品过渡基金保障模式研究——基于英国癌症药物基金的实证分析·····丁锦希, 吴逸飞, 李佳明, 等
1697 FDA对我国药品生产企业检查分析·····颜若曦, 曹轶, 董江萍

•新药注册与审评技术•

- 1702 关于流感疫苗保护性临床试验必要性的考虑·····刘波, 邓霞, 王远征, 等
1707 氯化钾缓释片人体生物等效性研究需关注的一些问题·····刘淑洁, 李敏, 马婧怡, 等
1711 肿瘤免疫治疗药物相关种属选择的一般考虑·····宫新江, 邵雪, 黄芳华, 等
1717 ICH指导原则S9转化实施需关注的问题·····叶旋, 张旻, 闫莉萍, 等

•重大新药创制专项巡礼•

- 1723 眼底疾病治疗药物非临床研究策略·····王若男, 钱仪敏, 宋硕, 等
1729 菊苣酸生物活性及其药理作用研究进展·····王玉真, 高爽, 李凌军, 等

•抗新型冠状病毒药物研究专栏•

- 1734 关于间充质干细胞治疗新型冠状病毒肺炎的临床试验的几点考虑·····高建超, 万志红, 黄云虹, 等
1738 新型冠状病毒肺炎相关临床试验研究进展·····娄宁, 韩晓红

•药物临床试验规范与进展专栏•

- 1746 国外创新药 I 期临床试验剂量探索设计方法及其对我国的启示·····刘晋, 杨嘉莹, 朱文博, 等
1752 中国临床研究协调员压力源特征研究·····张邦禹, 李玉平, 张鹏, 等

•临床研究•

- 1757 帕博利珠单抗注射液治疗恶性黑色素瘤安全性的Meta分析·····尹月, 赵志刚, 张艳华

•实验研究•

- 1764 一种头孢他啶晶体制备方法及晶体结构测定·····王琰, 张斗胜, 田冶, 等
1770 微流控芯片毛细管电泳法在酶法工艺青霉素类产品中残留蛋白检测的应用探讨·····王琰, 姚尚辰, 尹利辉, 等
1778 利用衰减全反射傅里叶变换红外光谱技术结合聚类分析快速评价头孢呋辛钠的质量·····王琰, 戚淑叶, 薛晶, 等
1785 柱前衍生化HPLC法测定天麻提取物中18种氨基酸含量·····蒋清伟, 王威, 刘姝畅, 等
1791 UPLC法同时测定缬沙坦氨氯地平片复方制剂的含量·····王威, 杜晓思

•药物安全与合理应用•

- 1795 替罗非班不良反应分析及预防对策·····杨效宇, 胡斌, 王惠川, 等

[期刊基本参数] CN11-2850/R*1992*sm*A4*120*zh*P*¥ 50.00**20*2020-08

责任编辑 赵文锐 英文审校 杜小莉 张鲸惊

- 1681 **Supervision and approval of advanced therapy medicinal products in European and its inspirations**
CHEN Yun, LI Shan-shan, SHAO Rong, *et al*
- 1691 **Research on the interim fund for high-value innovative drugs: based on the empirical study of cancer drugs fund in england**
DING Jin-xi, WU Yi-fei, LI Jia-ming, *et al*
- 1697 **Analysis of FDA inspection on pharmaceutical manufacturing industry in China**
YAN Ruo-xi, CAO Yi, DONG Jiang-ping
- 1702 **Considerations on the necessity of efficacy clinical trials for influenza vaccine**
LIU Bo, DENG Xia, WANG Yuan-zheng, *et al*
- 1707 **Considerations in bioequivalence study for potassium chloride sustained-release tablets**
LIU Shu-jie, LI Min, MA Jing-yi, *et al*
- 1711 **General considerations on the selection of relevant species for immune-oncology drugs**
GONG Xin-jiang, SHAO Xue, HUANG Fang-hua, *et al*
- 1717 **Specific considerations in the implementation of S9 in ICH guideline in China**
YE Xuan, ZHANG Min, YAN Li-ping, *et al*
- 1723 **Non-clinical research strategy for the treatment of fundus diseases**
WANG Ruo-nan, QIAN Yi-min, SONG Shuo, *et al*
- 1729 **Research advances on bioactivity and pharmacological effects of chicoric acid**
WANG Yu-zhen, GAO Shuang, LI Ling-jun, *et al*
- 1734 **Considerations on the clinical trials of mesenchymal stem cells for the treatment of novel coronavirus infected pneumonia in patients**
GAO Jian-chao, WAN Zhi-hong, HUANG Yun-hong, *et al*
- 1738 **Research progress in clinical trials of COVID-19**
LOU Ning, HAN Xiao-hong
- 1746 **Dose exploration design of phase I clinical trial of new drugs in foreign countries and its enlightenment to China**
LIU Jin, YANG Jia-ying, ZHU Wen-bo, *et al*
- 1752 **An analysis of job stressors for chinese clinical research coordinators**
ZHANG Bang-yu, LI Yu-ping, ZHANG Peng, *et al*
- 1757 **Safety of pembrolizumab in the treatment of advanced malignant melanoma: a Meta-analysis**
YIN Yue, ZHAO Zhi-gang, ZHANG Yan-hua
- 1764 **Preparation and structure determination of a crystal form of ceftazidime**
WANG Yan, ZHANG Dou-sheng, TIAN Ye, *et al*
- 1770 **Determination of residual proteins in the penicillin antibiotics produced by enzymatic process with microfluidic chip-based capillary electrophoresis**
WANG Yan, YAO Shang-chen, YIN Li-hui, *et al*
- 1778 **Rapid assessment on quality of cefuroxime sodium by ATR-FTIR combing with clustering analysis**
WANG Yan, QI Shu-ye, XUE Jing, *et al*
- 1785 **Determination of 18 amino acids in *Rhizoma gastrodiae* extract by precolumn derivation HPLC**
JIANG Qing-wei, WANG Wei, LIU Shu-chang, *et al*
- 1791 **Determination of valsartan and amlodipine in compound tablets using UPLC**
WANG Wei, DU Xiao-si
- 1795 **Analysis of tirofiban-induced adverse drug reactions and its preventive measures**
YANG Xiao-yu, HU bin, WANG Hui-chuan, *et al*

Directed by: National Medical Products Administration
Sponsored by: China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association
Editor-in-Chief: SANG Guo-wei
Board Chairman: SHI Sheng-yi
Edited by: Editorial Board of Chinese Journal of New Drugs
Published by: Chinese Journal of New Drugs Co., Ltd.
Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China
Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>
E-mail: bianjibu@newdrug.cn
Printer: Beijing Kexin Printing Co., Ltd.
Domestic Distribution: Beijing Post Offices
Overseas Distribution: China International Book Trading Corp.
(P.O.Box 399 Beijing, China)
Domestic Subscription: Local Post Offices
Periodical Registration: ISSN 1003-3734 CN 11-2850/R
Publication Date: August 15, 2020
Copyright: 2020 by Chinese Journal of New Drugs Co.,Ltd.